REGISTER NOW Irvine, California – Bioniz Therapeutics, Inc., is a clinical stage biopharmaceutical company developing...
Read More
IRVINE, Calif., May 12, 2021 – Bioniz Therapeutics, Inc., (“Bioniz”), a clinical-stage biopharmaceutical company advancing…
IRVINE, Calif., April 5 , 2021 – Bioniz Therapeutics, Inc., (“Bioniz”), a clinical-stage biopharmaceutical company…
Experienced drug developer, most recently at Almirall, to lead Bioniz’s clinical trials of novel, selective…
IRVINE, Calif., January 4, 2020 – Bioniz Therapeutics, Inc., (“Bioniz”), a clinical-stage biopharmaceutical company advancing…
- BNZ-1 showed an overall response rate (ORR) of 63.2% based on the Global Response…
As a multi-cytokine inhibitor, BNZ-1 is a novel immuno-oncology drug that integrates inhibition of malignant…
Irvine, California July, 2020– Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company developing first-in-class peptide…
Irvine, CA, January, 2020 – Bioniz Therapeutics, Inc., a privately held clinical stage biopharmaceutical company…
— BNZ-1, a Novel Multi-Cytokine Inhibitor of IL-2/9/15, Demonstrates Favorable Safety and Robust Pharmacodynamic Activity…
